Connect with us


Datacubed Health’s CEO, Brett Kleger, Talks China Expansion and Innovations in Healthcare Tech



Datacubed Health, a leading global provider of innovative solutions for patient engagement and data collection in clinical trials, recently announced the official launch of its eClinical platform app in China.

This milestone achievement represents a significant step forward for Datacubed Health’s commitment to expanding its presence in the Chinese market.

As part of this strategic move, Datacubed Health has joined forces with AppInChina, a renowned leader in Android App Store publication, ensuring seamless deployment of the eClinical platform app in official.

Android stores across China and the Apple App Store. This partnership guarantees accessibility to a wide range of devices and ecosystems.

Brett Kleger, CEO of Datacubed Health, shares insights with Ayesha Rashid at Digital Daily News about the upcoming innovations, global expansions, and how Datacubed Health caters to the diverse healthcare tech needs with its new eClinical platform app.

Datacubed Health’s mission is to “advance access to healthcare for everyone, everywhere.” How do the intersection of behavioural science and technology contribute to a more rewarding clinical trial experience, and how does this align with your mission?

The integration of behavioural science and technology plays a crucial role in advancing Datacubed Health’s mission to “advance access to healthcare for everyone, everywhere.”

By embedding behavioural science principles into our technology, we are able to foster a safe and inclusive digital space that accommodates people of all backgrounds, including varied races, genders, ages, religions and socioeconomic statuses.

Behavioural science offers insights into how individuals make decisions, interact with technology, and engage in health-related behaviours.

By understanding these patterns, we can design our technology to be more user-friendly, accessible, and engaging, ensuring that participants in clinical trials have a rewarding experience. This not only aids in retention and compliance but also contributes to the generation of high-quality data, which is essential for the advancement of medical research and the development of new treatments and interventions.

Furthermore, the principles of behavioural science guide us in creating interventions and supports that are tailored to the unique needs and preferences of diverse populations. This ensures that our technology is not only accessible but also equitable, promoting inclusivity and reducing disparities in healthcare access and outcomes.

In aligning with our mission, the intersection of behavioural science and technology enables us to break down barriers to healthcare access, ensuring that clinical trials are more representative of the populations they aim to serve. This not only enhances the generalizability and validity of research findings but also contributes to the development of interventions that are effective across diverse groups, ultimately advancing healthcare access and outcomes for everyone, everywhere.

Data privacy is a critical concern in the healthcare industry. How does Datacubed Health ensure the protection of patient data and maintain a safe and secure environment while collecting and utilizing this data for clinical trials and research?

Datacubed Health places paramount importance on data privacy in the healthcare industry, recognizing the sensitive nature of patient data in clinical trials and research. To ensure the protection of this data and maintain a safe, secure environment, the organization has implemented several key measures:

Quality Management System: Datacubed Health has established a robust Quality Management System that includes comprehensive policies, procedures, and controls. This system is designed to comply with various data privacy regulations, including the strict standards of 21CFR11 and Good Clinical Practices (GCPs). The establishment of this system demonstrates a commitment to maintaining the highest standards of data privacy and security.

Privacy and Security by Design: The platform development at Datacubed Health is grounded in principles that prioritize data privacy, security, and integrity from the outset. This approach ensures that these critical aspects are not afterthoughts but are integrated into the very fabric of the platform’s architecture and functionality.

Adherence to Industry-Best Security Practices: To safeguard the data, Datacubed Health employs industry-best security practices. This includes the encryption of data both in-transit and at-rest, providing robust protection against unauthorized access or breaches. Additionally, the organization conducts regularly scheduled penetration testing to identify and address vulnerabilities proactively. Continual threat monitoring is also in place to detect and respond to potential security threats promptly.

Minimisation and Pseudonymization of Personal Data: Each project undertaken by Datacubed Health is designed with the goal of minimizing the personal data collected. Moreover, the data that is collected is pseudonymized, adding an additional layer of security and privacy. This approach helps in reducing the risk of personal data being linked back to an individual, thereby enhancing privacy protection.

Restricted and Managed Access: Access to the collected data is tightly controlled and managed through a role-based access system. This means that only authorized personnel with specific roles and responsibilities can access the data, and even then, only the data necessary for their role. This system of restricted access ensures that the data is not only secure but also used appropriately and ethically within the confines of the project’s goals.

The launch of Datacubed Health’s eClinical platform app in China is a significant milestone. Could you share some specific features or capabilities of the app that make it particularly valuable for clinical trials in the Chinese market?

Firstly, we have ensured operational compliance by forming a strategic partnership with AppInChina, a leading entity in the domain of Android App Stores publication in China. This collaboration has enabled us to deploy our mobile applications across official Android stores in the region, as well as on the Apple App Store. This extensive support for a wide range of devices and ecosystems ensures that our platform is accessible to a broader audience, facilitating seamless participation in clinical trials.

In addition to this, Datacubed has solidified its presence in China through the establishment of a legal entity, obtaining all the necessary commercial and legal licenses and certificates required to operate our platform efficiently. This includes permissions to publish websites, process and store data locally, and distribute software applications, ensuring that we are fully compliant with Chinese regulations and ready to serve the local market.

Moreover, we achieved full software compliance, with our platform for China being meticulously customized to leverage software solutions that are compatible with local requirements. Our local Quality Assurance (QA) teams have rigorously tested the platform to ensure that it meets the stringent network security requirements and restrictions imposed by Chinese authorities, guaranteeing both compliance and optimal performance.

On the infrastructure front, we established a fully compliant and fault-tolerant Software as a Service (SaaS) infrastructure within China, hosting the Datacubed China solution on AWS Beijing. This strategic decision ensures that our platform is robust, reliable, and ready to handle the demands of clinical trials in the region.

We understand the importance of transparency and are more than willing to provide a comprehensive list of all the licenses, certificates, and compliance measures we have undertaken to ensure our platform is ready and reliable for use in China. Our commitment to compliance, combined with our innovative features and local adaptability, makes Datacubed’s eClinical platform app an invaluable tool for conducting clinical trials in the Chinese market.

Could you elaborate on how Datacubed Health ensures software compliance with Chinese regulations? What specific measures and customizations have been implemented to align with local requirements and network security restrictions?

In addition to what has already been stated, we have the following licenses/certifications in China ensuring software compliance.

1 – B22 Domestic Multi-party Communication Service License.

2 – B25 Commercial ICP License.

3 – Software Copyright Certificate.

4 – ICP Filing, PSB Filing, Chinese Domain Name, and Locally hosted Landing Page.

5 – Trademark.

6 – Local Hosting.

7 – Multi-level Protection Scheme (MLPS) Filing.

8 – Apple App Store China Operational Compliance.

The eClinical platform app is designed to bridge the gap between global research initiatives and the Chinese healthcare landscape. Could you provide examples of how this app is facilitating international collaboration and improving clinical research efforts in China?

Datacubed Health’s eClinical platform app is meticulously designed to seamlessly bridge the gap between global research initiatives and the unique healthcare landscape of China, ensuring robust international collaboration and enhancing clinical research efforts in the region.

First and foremost, it is imperative to emphasise that we are not cutting corners in any aspect of our operations. Our approach is thorough and meticulous, aimed at not just meeting, but exceeding both country-specific and local requirements in China. By navigating through the complex legal and regulatory landscape in China, we ensure a stable, reliable, and secure experience for patients participating in clinical trials.

Our unwavering commitment to doing things the right way translates into a consistent and uninterrupted access to our app for patients in the region. They will not face sudden access issues or experience any blackout service, which is a common concern in regions with stringent internet regulations. This reliability ensures that there are minimal to no delays for sponsors, facilitating a smoother progression of clinical trials.

Furthermore, our platform provides a superior, seamless experience for patients. We understand the importance of user experience in clinical trials, and our app is designed to be intuitive, easy to navigate, and user-friendly. This not only enhances participant engagement but also contributes to better data quality, which is crucial for the success of any clinical trial.

In terms of privacy and compliance, we have left no stone unturned. Our platform ensures the utmost protection of participant data while meticulously adhering to Chinese regulations. We have implemented robust data protection measures and encryption protocols to safeguard patient information, ensuring that their privacy is protected at all times.

By facilitating these measures, our eClinical platform app stands as a beacon of reliability, compliance, and user-friendliness, fostering international collaboration and significantly improving clinical research efforts in China. Our approach ensures that global research initiatives can seamlessly integrate with the Chinese healthcare landscape, contributing to the advancement of medical science and the betterment of patient outcomes.

With the launch of the eClinical platform app, what specific opportunities or challenges do you anticipate for Datacubed Health in the Chinese market, and how does the company plan to address them?

With the introduction of the eClinical platform app in the Chinese market, Datacubed Health is poised to tap into a realm of new opportunities, while also being mindful of the unique challenges that this landscape presents.

One of the challenges we have identified pertains to the availability of eConsent on our platform. Due to the stringent privacy laws in China, eConsent is currently unavailable, posing a challenge for consenting patients in remote studies. Recognising this, Datacubed Health is proactively working to provide comprehensive guidance to study teams on how to navigate this aspect, ensuring that they are well-equipped to manage the consenting process effectively.

Despite this challenge, our partnership with AppInChina has positioned us to overcome many common barriers that typically hinder market entry and operation in China. This strategic collaboration enhances our credibility and acceptance among Chinese Institutional Review Boards (IRBs), making it more likely for our solutions to receive approval. This is a significant advantage, as solutions set up in alternative regions like Taiwan often face resistance and are less likely to be approved.

In terms of market adoption, while there might be a slower uptake from sponsors based in China, we have observed a growing interest from large global sponsors looking to streamline their studies with sites in China. These sponsors recognize the value and efficiency that our platform brings to clinical trials, and are keen on leveraging our technology to enhance their research efforts in the region.

To address these challenges and capitalize on the opportunities, Datacubed Health is committed to continuous innovation and adaptation of our platform to meet the specific needs of the Chinese market. We are investing in local partnerships, engaging with regulatory bodies, and fine-tuning our platform to ensure compliance, reliability, and user-friendliness. Our goal is to provide a seamless, efficient, and compliant clinical trial experience for all stakeholders involved, ultimately contributing to the advancement of healthcare and research in China.

How does Datacubed Health’s eClinical platform app contribute to the overall advancement of healthcare accessibility and patient engagement, and what role does it play in the evolving landscape of healthcare technology?

Datacubed Health’s eClinical platform app significantly contributes to the advancement of healthcare accessibility and patient engagement, marking a pivotal role in the evolving landscape of healthcare technology. By bringing the app directly into patients’ homes, it enables participants to engage in clinical trials from any location, thereby greatly enhancing accessibility. This approach is particularly beneficial for those who might face geographical, logistical, or mobility challenges in attending clinical sites.

Furthermore, Datacubed Health has created a safe and inclusive digital space within the app. By being mindful and accommodating of age, race, gender, socioeconomic status the app ensures that a diverse range of participants can access and engage with clinical trials comfortably and confidently. This inclusivity is crucial in obtaining a broad, representative spectrum of data, which is essential for the efficacy and reliability of clinical research.

Patient engagement is another cornerstone of this platform. The app maintains continuous interaction with patients throughout the study, bridging the gaps often left by clinical sites. Clinical research studies, which can span several years, typically have periods where patients are not in direct contact with the study sites. During these intervals, Datacubed Health’s app plays a crucial role by providing ongoing content and study updates. This consistent engagement keeps patients informed, motivated, and connected to the study, which can significantly improve adherence and the quality of data collected.

Overall, the eClinical platform app from Datacubed Health represents a forward-thinking integration of technology and healthcare. By improving accessibility, promoting inclusivity, and ensuring continuous patient engagement, the app not only enhances the experience and effectiveness of clinical trials but also signals a broader shift towards a more patient-centric approach in healthcare technology.

What innovations or enhancements can we expect from Datacubed Health soon, both in terms of global expansion in Australia or around the world, and in addressing the specific needs of the global market?

Datacubed Health is actively focusing on global expansion and technological innovations to better serve the diverse needs of the global market. A key aspect of this strategy includes prioritizing expansion into Australia and the rest of the Asia Pacific region. This move is part of our broader vision to grow and serve a wider audience, bringing our advanced solutions to new markets and demographics.

In terms of technological advancements, Datacubed Health is placing a significant emphasis on enhancing efficiencies for sponsors and Contract Research Organizations (CROs). By harnessing the power of Generative AI, we are pioneering new ways to streamline processes and make data handling more efficient. However, it’s crucial to note that while we are excited about the potential of AI, we are equally committed to exploring this domain safely and responsibly, ensuring that our innovations align with ethical standards and global regulations.

Another area of focus is reducing translation timelines. As we expand our global footprint, it becomes increasingly important to ensure that our eCOA assessments are accessible and relevant to diverse patient populations. To this end, we are intensifying our efforts to shorten the translation timelines. This enhancement not only improves accessibility but also ensures that our assessments are culturally sensitive and accurately reflect the nuances of different regions. By doing so, we aim to provide more inclusive and reliable tools for patient assessment across various global markets while reducing study timelines for Sponsors.

Furthermore, we are continuously evolving our app to ensure it remains a digital safe space for all users. Recognizing the importance of retaining diverse patient populations in research studies, our app is designed to be inclusive, user-friendly, and sensitive to the varying needs of different communities. This commitment to diversity and inclusion is not just a part of our business ethos; it’s also a driving force behind our technological innovations and market strategies.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *


Which of the Following Will Destroy Most Food Allergens?



Which of the Following Will Destroy Most Food Allergens

Food allergens are substances found in certain foods that can trigger an immune response in individuals with food allergies. These allergens are typically proteins or protein fragments that the body mistakenly identifies as harmful, leading to various allergic reactions. Food allergies can range from mild symptoms like hives, itching, and digestive issues to severe and potentially life-threatening reactions, such as anaphylaxis.

The Importance of Addressing Food Allergens

With the increasing prevalence of food allergies, addressing food allergens has become a crucial concern for the food industry, healthcare professionals, and individuals living with these conditions. Effective methods to destroy or reduce the potency of food allergens can improve food safety, expand dietary options for those with allergies, and prevent potential life-threatening situations.

Common Food Allergens

Peanuts and Tree Nuts

Peanuts and tree nuts, such as almonds, walnuts, and cashews, are among the most common and severe food allergens. These allergens can cause severe reactions, including anaphylaxis, even with trace amounts.


Eggs, particularly the proteins found in egg whites (ovalbumin and ovomucoid), are another major food allergen. Egg allergies are prevalent in children, although some individuals may outgrow this allergy over time.

Milk and Dairy Products

Milk and dairy products contain several allergenic proteins, including casein and whey. Milk allergies are common in infants and young children but can persist into adulthood for some individuals.

Wheat and Gluten

Wheat and gluten, the protein found in wheat, barley, and rye, can trigger allergic reactions in individuals with wheat allergy or celiac disease. Gluten intolerance and sensitivity are also widespread concerns.


Soy is a common allergen, particularly in infants and children. Soy-based products, such as soy milk, tofu, and soy sauce, can cause allergic reactions in sensitive individuals.

Fish and Shellfish

Fish and shellfish, such as shrimp, crab, and lobster, are among the most potent food allergens. These allergens can cause severe and potentially life-threatening reactions, even with minimal exposure.

Methods to Destroy Food Allergens

While complete elimination of food allergens is challenging, various methods can effectively reduce or destroy their potency, making foods safer for individuals with allergies.

Heating and Cooking

Temperature and Duration

Heat treatment is one of the most common and effective methods for reducing or destroying food allergens. Many allergens are proteins, and exposing them to high temperatures can denature or break down their structure, rendering them less allergenic or non-allergenic.

The temperature and duration required to destroy food allergens vary depending on the specific allergen and the food matrix. For example, milk and egg allergens can be effectively reduced or eliminated by cooking at temperatures above 70°C (158°F) for several minutes. Peanut and tree nut allergens may require higher temperatures, typically above 90°C (194°F), to achieve significant allergen reduction.

However, it’s important to note that some allergens, particularly those found in certain seeds and legumes, can be more resistant to heat treatment and may require additional processing methods or a combination of techniques.


While heating and cooking can be effective in reducing or destroying food allergens, there are limitations to this method. Some heat-resistant allergens may remain allergenic even after extensive cooking. Additionally, certain foods or dishes may not be suitable for high-heat treatment due to quality or sensory considerations.

Chemical Treatments

Acidic Solutions

Exposing food allergens to acidic solutions, such as vinegar or citric acid, can potentially denature or break down the allergen proteins, reducing their allergenicity. This method is particularly effective for certain milk and egg allergens.

Enzymatic Treatments

Enzymatic treatments involve the use of specific enzymes that can selectively target and break down allergen proteins. For example, certain proteases (enzymes that break down proteins) have been shown to effectively reduce the allergenicity of milk, egg, and peanut allergens.


Ionizing Radiation

Ionizing radiation, such as gamma rays or electron beams, can be used to modify or degrade food allergens. This method works by disrupting the chemical bonds within the allergen proteins, potentially reducing their allergenicity.

The effectiveness of irradiation in destroying food allergens depends on factors such as the radiation dose, the type of allergen, and the food matrix. While this method has shown promising results in reducing allergens in certain foods, it may also affect other properties of the food, such as flavor, texture, and nutrient content.

Non-Ionizing Radiation

Non-ionizing radiation, such as ultraviolet (UV) light or pulsed light, has also been explored as a potential method for reducing or destroying food allergens. These methods can disrupt the structure of allergen proteins through photochemical reactions, rendering them less allergenic.

However, the effectiveness of non-ionizing radiation can vary depending on the specific allergen and food matrix, and further research is needed to fully understand its potential and limitations.

Processing and Manufacturing

High-Pressure Processing (HPP)

High-pressure processing (HPP) is a non-thermal food preservation technique that subjects foods to extremely high pressures, typically ranging from 400 to 800 megapascals (MPa). This process can cause structural changes in allergen proteins, potentially reducing their allergenicity.

HPP has shown promising results in reducing the allergenicity of various foods, including milk, eggs, and peanuts. However, the effectiveness can vary depending on the specific allergen, food matrix, and processing conditions.


Extrusion is a manufacturing process that involves forcing food materials through a die or small opening under high temperature and pressure. This process can potentially denature or degrade allergen proteins, reducing their allergenicity.

While extrusion has been explored for reducing allergens in certain foods, such as wheat and soy products, its effectiveness may depend on various factors, including the specific allergen, extrusion conditions, and food composition.

Factors Influencing the Effectiveness of Allergen Destruction

The effectiveness of any method in destroying food allergens can be influenced by several factors, including:

Food Matrix and Composition

The food matrix and composition can impact the accessibility and susceptibility of allergens to various treatments. For example, allergens present in complex food matrices or surrounded by other food components may be more resistant to certain methods.

Allergen Concentration

The concentration of allergens in a food can influence the effectiveness of the destruction method. Higher concentrations of allergens may require more intensive or prolonged treatments.

Processing Conditions

Specific processing conditions, such as temperature, duration, pressure, pH, and the presence of other substances (e.g., enzymes, chemicals), can significantly affect the efficacy of allergen destruction methods. Optimizing these conditions is crucial for achieving the desired level of allergen reduction or elimination.

Challenges and Considerations

While various methods exist for destroying or reducing food allergens, there are several challenges and considerations to address:

Regulatory Guidelines

Food allergen labeling and regulations vary across different countries and regions. It is essential to comply with the relevant guidelines and regulations when implementing allergen destruction methods in food production. Validation and monitoring procedures may be required to ensure the safety and accuracy of allergen claims.

Food Safety and Quality

Certain methods for destroying food allergens, such as chemical treatments or irradiation, may potentially introduce new safety concerns or affect the overall quality and sensory properties of the food. It is crucial to carefully evaluate the impact of these methods on food safety, nutritional value, and consumer acceptance.

Regulatory Guidelines

Food allergen labeling and regulations vary across different countries and regions. It is essential to comply with the relevant guidelines and regulations when implementing allergen destruction methods in food production. Validation and monitoring procedures may be required to ensure the safety and accuracy of allergen claims.

Food Safety and Quality

Certain methods for destroying food allergens, such as chemical treatments or irradiation, may potentially introduce new safety concerns or affect the overall quality and sensory properties of the food. It is crucial to carefully evaluate the impact of these methods on food safety, nutritional value, and consumer acceptance.

Consumer Acceptance

While reducing or eliminating food allergens can expand dietary options for individuals with allergies, consumer acceptance of the methods used and potential changes in food properties should be considered. Transparent communication and education about the safety and efficacy of allergen destruction methods may be necessary to gain consumer trust and confidence.

People Also Read:


Destroying food allergens is a complex challenge that requires a combination of various methods and careful consideration of factors such as the specific allergen, food matrix, processing conditions, and regulatory guidelines. While no single method can eliminate all allergens, the techniques discussed, including heat treatment, chemical treatments, irradiation, and advanced processing methods, offer promising solutions for reducing the allergenicity of foods.

Effective allergen destruction can improve food safety, expand dietary options for individuals with food allergies, and facilitate the development of new products that meet the needs of this growing consumer segment. However, it is crucial to strike a balance between allergen reduction and maintaining food quality, safety, and consumer acceptance.

Ongoing research and collaboration between the food industry, regulatory bodies, and scientific communities are essential to continually refine and optimize allergen destruction methods, ensuring a safer and more inclusive food supply for all.


Can cooking completely eliminate all food allergens?

While cooking and heat treatment can effectively reduce or destroy many food allergens, it is important to note that some allergens may be more resistant to heat and may require additional processing methods or a combination of techniques. Complete elimination of allergens through cooking alone may not be possible for certain foods or allergens.

Are chemical treatments safe for destroying food allergens?

Chemical treatments, such as the use of acidic solutions or enzymes, can be effective in reducing or destroying food allergens. However, it is crucial to ensure that these treatments are carefully controlled and comply with food safety regulations. Any residual chemicals or byproducts should be within safe limits and not pose additional health risks.

Can irradiation affect the nutritional value of food?

Irradiation, particularly ionizing radiation, can potentially affect the nutritional value of food by degrading certain vitamins and other nutrients. The extent of nutrient loss depends on factors such as the radiation dose, food composition, and storage conditions. Careful consideration and monitoring of potential nutrient losses are necessary when using irradiation for allergen destruction.

Are there any risks associated with high-pressure processing (HPP) for allergen reduction?

High-pressure processing (HPP) is generally considered a safe and effective method for reducing food allergens. However, it is important to ensure that the processing conditions are properly controlled and validated. Potential risks may include the introduction of contaminants or the formation of undesirable compounds if the processing parameters are not optimized.

How can consumers identify products that have undergone allergen destruction processes?

Regulatory bodies and food labeling guidelines play a crucial role in informing consumers about the allergen status of food products. Products that have undergone allergen destruction processes should be clearly labeled with accurate and transparent information about the methods used and the potential presence of residual allergens.

Continue Reading


Zepp Health Launches Zepp OS 3.5 with Zepp Flow™



Zepp Health Corporation (“Zepp Health”) (NYSE: ZEPP), a global leader in smart wearables and health technology, today announces a significant stride in wearable intelligence with the introduction of Zepp OS 3.5, featuring Zepp Flow™. This revolutionary enhancement brings a whole new level of interaction to wearable devices, marking a pioneering advancement in the industry, making Zepp Health’s Amazfit smartwatches the first to have a fully integrated Natural-Language User Interface (LUI) powered by LLM AI in its operating system.

Zepp Flow™, the centerpiece of Zepp OS 3.5, represents much more than just a voice assistant; it embodies a paradigm shift in user experience. Inspired by the concepts of balance and harmony, the name “Flow” encapsulates the smooth and intuitive nature of user interaction. Much like the effortless movement of water or the focused energy experienced in a state of “flow,” Zepp Flow™ facilitates a seamless connection between users and their devices, allowing for natural, uninterrupted interaction.

Designed to understand natural language, Zepp Flow™ eliminates the need for predefined commands or keywords, enabling users to express their intentions freely. By intuitively interpreting user requests, whether it’s initiating a workout or managing daily tasks, Zepp Flow™ streamlines the user experience, making it more intuitive and effortless than ever before. This breakthrough represents a significant leap towards a future where artificial intelligence seamlessly integrates into everyday life, particularly in health, fitness, and productivity domains.

A Future of Connectivity and Intelligence

With a global presence spanning over 90 countries and a user base exceeding 42 million, Zepp Health, through its renowned brands like Amazfit, is committed to redefining the way individuals approach their health and wellness. By harnessing advanced technology and fostering collaboration across its brand portfolio, Zepp Health is at the forefront of innovation, shaping the future of wearable technology.

Through Zepp Flow™, Zepp Health continues to push the boundaries of wearable technology, empowering users to seamlessly integrate smart devices into their daily lives. Zepp Flow™ represents a significant milestone in wearable intelligence, embodying the seamless integration of AI into people’s everyday lives. “With dedicated R&D teams across North America, Europe, and Asia, we are committed to driving innovation and delivering unparalleled user experiences, to bring intelligent healthcare solutions empowering people to take control of their well-being,” said Wayne Huang, CEO of Zepp Health. He added, “Zepp Flow™ epitomizes our dedication to unified connectivity and intelligent functionality throughout our ecosystem. Expanding its reach from the Zepp OS on smartwatches to the Zepp App on smartphones, and integrating with natural language processing, Zepp Flow™ asserts itself as the omnipresent AI within our system. Whether it resides on your smartwatch, earbuds, our app on your phone, or in the cloud, Zepp Flow™ guarantees a seamless and intuitive experience across all platforms.”

How Zepp Flow™ Works

Zepp Flow™ boasts several key features that redefine user experience:

  1. Natural Conversation: Unlike traditional voice assistants, Zepp Flow™ allows users to express themselves freely without requiring specific command phrases.
  2. Efficient Recognition: Zepp Flow™ rapidly and accurately recognizes user speech, ensuring a smooth and responsive interaction.
  3. Precise Understanding: Users need only describe what they want, and Zepp Flow™ will recognize their intent and provide the most appropriate response.


  • Zepp OS 3.5 and Zepp Flow™ will be supported on the Amazfit Balance in the US, Canada, United Kingdom and Republic of Ireland, via a firmware update on February 26th.
  • Amazfit Balance users in France, Italy, Germany, Spain, Liechtenstein, Luxembourg, Monaco, Switzerland, Andorra, Austria, Belgium, and San Marino will be able to upgrade to Zepp OS 3.5 on May 1st.
  • The Amazfit Cheetah series, Amazfit Falcon, and Amazfit T-Rex Ultra will receive this update on a rolling basis, starting from May 28th through until June 11th. The Amazfit Active will be upgraded on June 20th.

About Zepp Health Corporation

Zepp Health (NYSE:ZEPP), a global smart wearable and health technology leader, empowers users to live their healthiest lives by optimizing their health, fitness, and wellness journeys through its leading consumer brands, Amazfit, Zepp Clarity, and Zepp Aura. Powered by its proprietary Zepp Digital Health Management Platform, which includes the Zepp OS, AI chips, biometric sensors, and data algorithms, it delivers cloud-based 24/7 actionable insights and guidance to help users attain their wellness goals. To date, Zepp Health has shipped over 200 million units and its products are available in 90+ countries. Founded in 2013, Zepp Health has offices across the Americas, EMEA, and APAC regions. For more information, visit


Continue Reading


Huawei Launches Medical Tech Solution for Intelligent Healthcare



During MWC Barcelona 2024, Huawei officially launched its Medical Technology Digitalization Solution as part of its effort to lead the digital and intelligent upgrade of the healthcare industry.

David Shi, Vice President of Huawei's ICT Marketing & Solution Sales

David Shi, Vice President of Huawei’s ICT Marketing & Solution Sales, said, “To accelerate the intelligent upgrade of the healthcare industry, Huawei, as an ICT provider, builds a secure and sustainable digital foundation for the healthcare industry and helps it go intelligent.” He emphasized that together with partners, Huawei aims to help its customers succeed.

Thousands of images read in seconds, accelerating the digital & intelligent upgrade of medical technology services

The medical technology digitalization solution focuses on pathology and medical imaging. The solution has three competitive advantages: SmartCache intelligent pre-reading, which improves image reading efficiency and achieves zero latency during data retrieval; the Huawei-developed compression algorithm, which saves 30% storage and 70% cabinet space; and video-network synergy, which supports consistent remote diagnosis to promote hierarchical diagnosis and treatment.

This solution has been applied in many healthcare institutions around the world. Huawei helped Ruijin Hospital build a digital smart pathology department, which enables the concurrent access of 1000+ pathological sections within one second. This improved the retrieval speed by 80 times. Huawei helped the Health Bureau of Longgang District, Shenzhen build a regional medical imaging platform. It supports the interconnection and sharing of medical image data among 12 hospitals, one-click access to image reports, and mutual recognition of cross-hospital examinations.

Deep scenario-technology integration and innovative upgrade of three solutions

Huawei leverages cloud-network-edge-device synergy to dig deep into service scenarios and upgrade three major solutions.

The Smart Ward Solution looks to Wi-Fi, IoT, and multi-band convergence in one network to support data collection for more than 400 terminals, delivering high-quality diagnosis and treatment.

The Smart Hospital Campus Solution uses the digital platform to streamline campus operations subsystems, achieving all-scenario intelligent services and E2E refined operations.

The One Hospital, Multiple Branches Solution builds an integrated cloud-network-edge resource base to implement unified management as well as diagnosis and treatment services of the same quality across different hospital branches.

So far, Huawei has served over 5000 hospitals and medical institutions in more than 110 countries and regions.

Continue Reading